ArticleBMC cancer2019
Effect of prior cancer on survival outcomes for patients with pancreatic adenocarcinoma: a propensity score analysis.
Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 31 citations in OpenAlex.
- Prior Cancer and Survival in Patients With Esophageal Squamous Cell Carcinoma.JAMA network open · 2026Article
- Clinical characterization and prognostic modeling of bladder cancer patients with a history of prior tumors: a SEER database analysis.Translational cancer research · 2025Article
- The effect of thyroid cancer on the survival of patients with digestive system tumors using SEER database.Scientific reports · 2024Article
- Incidence and survival of second primary non-Hodgkin lymphoma: A Surveillance, Epidemiology, and End Results-based cohort study.PloS one · 2024Article
- Medical history of thyroid cancer does not impair prognosis in non-metastatic breast cancer patients: an analysis study based on SEER database and external cohort.Frontiers in oncology · 2024Article
- Survival of cancer survivors with a new pancreatic cancer diagnosis.Cancer medicine · 2023Article
- Effect of prior cancer history on survival of patients with esophageal carcinoma: a propensity score matching, population-based study.Journal of thoracic disease · 2022Article
- Association between Prior Malignancy Exclusion Criteria and Age Disparities in Cancer Clinical Trials.Cancers · 2022Article
- Effect of prior malignancy on the prognosis of gastric cancer and somatic mutation.World journal of clinical cases · 2022Article
- Article
- Effect of prior cancer on survival of hepatocellular carcinoma: implications for clinical trial eligibility criteria.BMC cancer · 2021Article
- The impact of a prior malignancy on outcomes in gastric cancer patients.Cancer medicine · 2021Article
- The Effect of 10 Most Common Nonurological Primary Cancers on Survival in Men With Secondary Prostate Cancer.Frontiers in oncology · 2021Article
- The effects of a prior malignancy on the survival of patients with ovarian cancer: a population-based study.Journal of Cancer · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
backgroundWith the increase in cancer survivors, more pancreatic ductal adenocarcinomas (PDACs) are developing as second primary cancers. Whether a prior cancer has an inferior impact on survival outcomes in patients with PDAC remains unknown, and the validity of criteria used to exclude patients with prior cancers in clinical trials needs to be determined. The aim of this study was to evaluate the prognostic factors and assess the survival impact of a prior cancer in patients with second primary PDAC.
methodsPatients with PDAC were retrospectively selected from the Surveillance, Epidemiology, and End Results (SEER) database. Overall survival (OS) and cancer-specific mortality rates were compared between patients with and those without prior cancer.
resultsThe data of 9235 patients with PDAC from 2004 to 2015 were retrieved from the SEER database, consisting of 438 (4.74%) patients with a prior cancer and 8797 (95.26%) patients without a prior cancer, the patients were then pair-matched using propensity score matching (PSM) analysis. The median OS rates were 7 months for both groups of patients with PDAC with and without prior cancer. These two groups of patients had similar survival rates and cancer-specific mortalities before and after the PSM analysis. In the multivariate analysis, a history of prior cancer was not a significant prognostic factor of OS in patients with PDAC.
conclusionsPatients with PDAC who had a prior cancer had similar OS and cancer-specific mortality rates as those of patients without a prior cancer. The inclusion of patients with a prior cancer in the clinical trials of PDAC should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.